Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05265052 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to Dec 2026
    • Start date: Dec 2025 to Dec 2026
    • Secondary endpoints: 14 to 13
    v8
  2. Start date: Mar 2025 to Dec 2025v7
  3. Start date: Sep 2024 to Mar 2025
    • Primary completion date: Jun 2025 to Dec 2025
    • Study completion date: Sep 2025 to Dec 2025
    v6
  4. Primary completion date: Jun 2024 to Jun 2025
    • Start date: Sep 2023 to Sep 2024
    • Study completion date: Sep 2024 to Sep 2025
    v5
  5. Primary completion date: Jun 2023 to Jun 2024
    • Start date: Sep 2022 to Sep 2023
    • Study completion date: Sep 2023 to Sep 2024
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Mar 2022 to Sep 2022
    • Primary completion date: Dec 31, 2022 to Jun 2023
    • Study completion date: Apr 5, 2023 to Sep 2023
    v3
  2. Start date: Mar 1, 2022 to Mar 2022
    • Secondary endpoints: details revised at 2 of 14 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Trial Details
NCT Number NCT05265052
Lead Sponsor 3D Medicines
Conditions
(from sponsor)		 Cancer Pain
Related terms Cancer Pain
Enrollment 177 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov